FDA Approves EVEROLIMUS — Aurobindo Pharma Limited

# FDA Approves Aurobindo Pharma's Generic Everolimus, Expanding Competitive Landscape for Immunosuppressant Market The U.S. Food and Drug Administration has approved Aurobindo Pharma Limited's abbreviated new drug application (ANDA219533) for oral everolimus, a move expected to intensify generic competition in the immunosuppressant and anti-cancer therapy segments and potentially pressure pricing for the branded version. The approval marks another significant entry by the Indian pharmaceutical manufacturer into the U.S. specialty generic market, where everolimus is used across multiple